Last updated on April 17, 2014 at 11:16 EDT

Latest Otsuka Pharmaceutical Europe Ltd. Stories

2012-06-15 10:23:01

PARIS, June 15, 2012 /PRNewswire/ -- Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec(R)...